

CELL BIOTECH

Probiotics & Microbiome company



2025 3Q Earnings Release

2025. 11.

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual results to differ from those stated or implied in this material.

3q Earnings Summary

CELL BIOTECH

Revenue up 26.3% to KRW 15.4 billion, operating profit up 6.3% to KRW 2.2 billion

Domestic revenue up 15.6%, overseas revenue up 34.2%

Duolac brand sales up 23.7% to KRW 6.8 billion, OEM/ODM sales up 32.6%

to KRW 7.3 billion, Raw material sales up 6.3% to KRW 1.2 billion

(unit : KRW 100 mil)

	2024 3q	매출비중(%)	2025 3q	매출비중(%)	YoY(%)
매출액	121.6		153.6		26.3
국내	51.8	42.6	59.9	39.0	15.6
해외	69.8	57.4	93.7	61.0	34.2
	2024 3q	이익률(%)	2025 3q	이익률(%)	YoY(%)
영업이익	20.9	17.2	22.2	14.5	6.3
순이익	9.7	8.0	34.5	22.5	256.0


Revenue trends

CELL BIOTECH

3q revenue KRW 15.3 billion, yoy +26.3%, qoq +28.9%


Quarterly revenue

(unit : KRW mil)



Full year revenue

(unit : KRW mil)



Profit trends


CELL BIOTECH

3q operating profit KRW 2.2 billion, yoy +6.1%

Net Profit KRW +3.4 bil.


Quarterly profit

(unit : KRW mil)



Full year profit


(unit : KRW mil)



Revenue breakdown

CELL BIOTECH

3q revenue of Duolac brand +23.7% to 6.9 KRW bil., OEM/ODM +32.6% to 7.3 KRW bil., and raw material +6.3% to 1.2 KRW bil.



Business update

CELL BIOTECH

Microbiome R&D

- 1) Microbiome First-in-Class anticancer pipeline 'PP-P8'
clinical phase 1 IND submitted (Mar 5, 2021)
- 2) Acquisition European patent of PP-P8 (Apr 1, 2021)
(patent number EP3453718)
- 3) Acquired US patent for Probiotics drug delivery system
(22. 12. 20)
- 4) P8 anticancer mechanism paper MOA (23.06.07)
Anti-Cancer Roles of Probiotic-Derived P8 Protein in
Colorectal Cancer Cell Line DLD-1, Int. J. Mol. Sci, 2023
- 5) Cellbiotech, Colorectal Cancer Drug Phase 1 Clinical Trial
Plan Approved by Korea MFDS (Mar 20, 2024)
- 6) Cellbiotech starts phase 1 of microbiome colorectal
cancer drug 'PP-P8'

<https://www.hankyung.com/article/202502194939i>

No. 1 in global export for 12 consecutive years

- 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world
for 12 consecutive years



<https://www.mk.co.kr/en/it/11341049>

FDA GRAS World's Most Listed

1) Cellbiotech "11 types of lactic acid bacteria secured FDA GRAS certification... The World's Largest Holdings"



<https://www.hankyung.com/article/202402222016i>

2) Cellbiotech, Probiotics Leading... Global Leap



<https://www.dailypharm.com/Users/News/NewsView.html?ID=309331&REFERER=NP>

Consolidated Financial Summary

CELL BIOTECH

Income statement

(unit : KRW 100 mil., %)

	2024 3q		2025 3q	
	Amount	Ratio	Amount	Ratio
Revenue	121.6	100.0	153.6	100.0
Gross profit	86.7	71.3	110.3	71.9
SG&A expenses	65.9	54.1	88.2	57.4
Operating profit	20.9	17.2	22.2	14.4
Consolidated net income	9.7	8.0	34.5	22.5

Statement of financial position

(unit : KRW 100 mil., %)

	2024 .12	2025 3q
Assets	1,304	1,346
Current Assets	971.48	1,011
Non current Assets	332.49	335
Liabilities	62.28	75
Current Liabilities	58.62	74
Non current Liabilities	3.66	1
Shareholder's Equity	1,242	1,271